We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current BRIBF market cap is 133.67M. The company's latest EPS is CNY -0.2396 and P/E is -0.75.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Revenue | 0 | 0 | 0 | 51.63M | 617k |
| Operating Income | -126.92M | -911.88M | -642.61M | -513.85M | -544.3M |
| Net Income | -521.03M | -1.19B | -4.16B | -484.31M | -174.83M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Assets | 1.04B | 1.27B | 3.61B | 3.39B | 3.2B |
| Total Liabilities | 1.65B | 3.01B | 300.44M | 234.35M | 125.87M |
| Total Equity | -612.76M | -1.74B | 3.31B | 3.16B | 3.07B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Operating | -67.28M | -403.72M | -879.46M | -496.28M | N/A |
| Investing | -92.78M | -43.65M | -475.76M | -1.43B | N/A |
| Financing | 518.35M | 657M | 3.23B | -3.04M | N/A |
| Market Cap | 133.67M |
| Price to Earnings Ratio | -0.75 |
| Price to Sales Ratio | 225 |
| Price to Cash Ratio | 0.27 |
| Price to Book Ratio | 0.04 |
| Dividend Yield | - |
| Shares Outstanding | 729.64M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 76.16k |
| 52 Week Change | -56.32% |
| 52 Week High | 0.4875 |
| 52 Week Low | 0.1667 |
| Spread (Intraday) | 0.3 (85.71%) |
| Company Name | Brii Bioscience Ltd (PK) |
| Address |
po box 309 grand cayman KY1 – 1104 |
| Website | https://www.briibio.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
